The Correlations Between Early Enteral Nutrition & Intra-abdominal

Status Completed

Clinical Trial Summary

As an important management of severe acute pancreatitis (SAP), enteral nutrition (EN), especially early enteral nutrition (EEN) increases the blood flow of gut mucosa and stimulates the intestinal motility. Moreover, EEN maintains the gut integrity, prevents bacterial and endotoxin translocation and thereby theoretically reduces the incidence of infections. Therefore, EEN has the ability to reduce the infectious complications, length of hospital stay and mortality of patients with SAP.

However, the role of EEN is considered to be influenced by intra-abdominal hypertension (IAH) in patients with SAP. The previous studies showed that gut was the most sensitive splanchnic organ to the increase of intra-abdominal pressure (IAP). When IAH occurs, it reduces the blood flow of gut, and then results in the development of intestinal ischemia and edema. The hypoxia and hypoperfusion of intestine leads to the increase of permeability of the intestinal mucosal barrier, and then leads to bacterial translocation. Therefore, IAH could result in the gastrointestinal dysfunction. Nevertheless, the different impacts of specific IAP values on the tolerance of EEN have not been reported.

Furthermore, the effects of early enteral feeding on the IAP in SAP also remain unknown. Due to the severe inflammatory response of SAP, could EEN increase the burden of bowel, cause expansion of intestinal cavity, thus increase IAP? However, there were rare literatures up to date reporting the association between EEN and IAH in patients with SAP. Therefore, the present study aimed to investigate the influence of specific IAP on the tolerance of early enteral feeding, as well as the effects of EEN on IAP in SAP patients. Moreover, the impacts of EEN on the disease severity and clinical outcome of SAP were also researched.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01507766
Study type	Interventional
Source	Nanjing University School of Medicine
Contact
Status	Completed
Phase	Phase 4
Start date	September 2010
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05410795` - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting	`NCT04195347` - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase	Phase 1/Phase 2
Completed	`NCT04735055` - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed	`NCT02928718` - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated	`NCT02885441` - Treatment of Acute Pancreatitis With Ketorolac	Phase 4
Completed	`NCT02563080` - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting	`NCT01626911` - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis	N/A
Completed	`NCT04901949` - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting	`NCT04814693` - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis	N/A
Completed	`NCT02743364` - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis	Phase 2
Recruiting	`NCT05281458` - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections	N/A
Not yet recruiting	`NCT04990336` - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis	N/A
Not yet recruiting	`NCT03259880` - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals	N/A
Completed	`NCT02543658` - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension	Phase 2
Recruiting	`NCT06023771` - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting	`NCT05501314` - Remote Home Monitoring Acute Pancreatitis	N/A
Completed	`NCT02897206` - Imipenem Prophylaxis in Patients With Acute Pancreatitis	Phase 4
Recruiting	`NCT03634787` - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting	`NCT04989166` - Effect of Nano-curcumin Supplementation in Acute Pancreatitis	N/A
Recruiting	`NCT05613673` - Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms